EFFICACY AND SAFETY OF TREATMENT WITH BEVACIZUMAB (BEV) plus CHEMOTHERAPY (CT) BEYOND FIRST PROGRESSION IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC) PREVIOUSLY TREATED WITH BEV plus CT: AGE SUBGROUP ANALYSIS FROM A RANDOMISED PHASE III INTERGROUP STUDY (ML18147)

被引：0
|
作者：
Bouche, O. [1 ]
Steffens, C. [2 ]
Andre, T. [3 ,4 ]
Bennouna, J. [5 ]
Sastre, J. [6 ]
Osterlund, P. [7 ]
von Moos, R. [8 ]
Reyes-Rivera, I. [9 ]
Sersch, M. A. [10 ]
Arnold, D. [11 ]
机构：
[1] Ctr Hosp Univ Robert Debre, Serv Hepatogastroenterol & Cancerol Digest, Reims, France
[2] MVZ Haematol Onkol Klin Dr Hancken, Stade, Germany
[3] Hop St Antoine, F-75571 Paris, France
[4] Univ Paris 06, Paris, France
[5] Inst Cancerol Ouest, Nantes, France
[6] Serv Oncol Med HC, Madrid, Spain
[7] Univ Helsinki, Cent Hosp, Helsinki, Finland
[8] Kantonal Hosp Graubunden, Chur, Switzerland
[9] Genentech Inc, Stat, San Francisco, CA 94080 USA
[10] Genentech Inc, Global Dev, San Francisco, CA 94080 USA
[11] Univ Canc Ctr Hamburg, Hubertus Wald Tumor Ctr, Hamburg, Germany
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：190 / 191
页数：2
相关论文
共 50 条
  • [1] BEVACIZUMAB (BEV) plus CHEMOTHERAPY (CT) BEYOND FIRST PROGRESSION IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC) PREVIOUSLY TREATED WITH BEV-BASED THERAPY: OVERALL SURVIVAL SUBGROUP FINDINGS FROM ML18147
    Vieitez de Prado, J. M.
    Borg, C.
    Arnold, D.
    Greil, R.
    Van Cutsem, E. J. D.
    von Moos, R.
    Bennouna, J.
    Reyes-Rivera, I.
    Bendahmane, B.
    Kubicka, S.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 193 - 193
  • [2] BEVACIZUMAB (BEV) plus CHEMOTHERAPY (CT) BEYOND FIRST PROGRESSION IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC) PREVIOUSLY TREATED WITH FIRST-LINE BEV plus CT (ML18147): EFFICACY AND SAFETY ANALYSES BY OXALIPLATIN VS IRINOTECAN-BASED CT
    Osterlund, P.
    Alonso-Orduna, V.
    Schlichting, C.
    Andre, T.
    Sastre, J.
    Greil, R.
    Kubicka, S.
    Reyes-Rivera, I.
    McCall, B.
    Van Cutsem, E. J. D.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 195 - 195
  • [3] Bevacizumab (BEV) continued beyond first progression in patients (pts) with metastatic colorectal cancer (mCRC) previously treated with BEV plus chemotherapy (CT): Biomarker findings from ML18147.
    Kubicka, Stefan
    Von Moos, Roger
    Greil, Richard
    Sastre, Javier
    Osterlund, Pia J.
    Arnold, Dirk
    Andre, Thierry
    Van Cutsem, Eric
    Mueller, Thomas
    Reyes-Rivera, Irmarie
    Bennouna, Jaafar
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [4] Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: Results of a randomized phase III intergroup study (TML study).
    Arnold, Dirk
    Andre, Thierry
    Bennouna, Jaafar
    Sastre, Javier
    Osterlund, Pia J.
    Greil, Richard
    Van Cutsem, Eric
    Von Moos, Roger
    Reyes-Rivera, Irmarie
    Bendahmane, Belguendouz
    Kubicka, Stefan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [5] Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: results of a randomised phase III intergroup study initiated by the AIO and AGMT (ML18147)
    Greil, R.
    Arnold, D.
    Hegewisch-Becker, S.
    Freier, W.
    Steffens, C. -C.
    Bertram, M.
    Schlichting, C.
    Andel, J.
    Taylor, M.
    Makrutzki, M.
    Kubicka, S.
    [J]. ONKOLOGIE, 2012, 35 : 254 - 254
  • [6] Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings
    Kubicka, S.
    Greil, R.
    Andre, T.
    Bennouna, J.
    Sastre, J.
    Van Cutsem, E.
    von Moos, R.
    Oesterlund, P.
    Reyes-Rivera, I.
    Mueller, T.
    Makrutzki, M.
    Arnold, D.
    [J]. ANNALS OF ONCOLOGY, 2013, 24 (09) : 2342 - 2349
  • [7] Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first disease progression (PD) in patients with metastatic colorectal cancer (mCRC) previously treated with BEV-based therapy: Outcomes according to KRAS status and first-line CT backbone in the ML18147 study.
    Kubicka, Stefan
    Greil, Richard
    Andre, Thierry
    Bennouna, Jaafar
    Sastre, Javier
    Van Cutsem, Eric
    Von Moos, Roger
    Osterlund, Pia J.
    Hegde, Priti
    Sersch, Martina A.
    Osborne, Stuart
    Hermann, Frank
    Arnold, Dirk
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [8] Efficacy and safety of bevacizumab (BEV) plus chemotherapy in Chinese patients (pts) with metastatic colorectal cancer (mCRC): Results from the ARTIST study.
    Guan, Z.
    Xu, J.
    Luo, R.
    Feng, F.
    Wang, L.
    Shen, L.
    Yu, S.
    Ba, Y.
    Liang, J.
    Wang, D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [9] A phase Ib study of the safety and efficacy of atezolizumab (atezo) plus bevacizumab (bev) plus cobimetinib (cobi) in patients (pts) with metastatic colorectal cancer (mCRC)
    Bendell, J.
    Lieu, C.
    Raghav, K. P. S.
    Argiles, G.
    Cubillo, A.
    Qu, X.
    Yan, Y.
    Merchant, M.
    Zeuner, H.
    Gallo, J. D.
    Segal, N. H.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [10] FOLFOXIRI plus bevacizumab (BEV) in patients (pts) with previously untreated metastatic colorectal cancer (mCRC): Preliminary safety results from the OPAL study
    Stein, Alexander
    Atanackovic, Djordje
    Hildebrandt, Bert
    Stuebs, Patrick
    Steffens, Claus-Christoph
    Brugger, Wolfram
    Hapke, Gunnar
    Illerhaus, Gerald
    Bluemner, Ernst
    Bokemeyer, Carsten
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
12345